| 1 | Renal Impairment and Late Toxicities Comparing Contemporary Chemotherapy Regimens for Testicular Cancer in a Real-World Setting. (Kerns SL, Dinh PC Jr, Monahan PO, Fung C, Sesso HD, Feldman DR, Hamilton RJ, Vaughn DJ, Kollmannsberger C, Martin NE, Einhorn LH, Travis LB) J Natl Compr Canc Netw 2026 Feb 13;24(3):81-90 2 Citations |
| 1 | Phase II Study of Low-Dose Paclitaxel and Cisplatin in Combination With Split-Course Concomitant Twice-Daily Reirradiation in Recurrent Squamous Cell Carcinoma of the Head and Neck: Long-term Follow-up of NRG Oncology RTOG 9911. (Langer CJ, Harris J, Horwitz EM, Kies M, Ad VB, Wong SJ, Caudell JJ, Zeitzer KL, Spencer SA, Zhang Q, Yom SS, Le QT) Int J Radiat Oncol Biol Phys 2026 Jan 01;124(1):50-60 2 Citations |
| 1 | Sarcopenia, Elevated Body Mass Index, and Platinum-Associated Adverse Events in Patients With Lung Cancer. (Lyu J, Mantz L, Katz-Agranov NS, Ouyang T, Hanna PE, Mejia SM, Moreno D, Lee M, Cao A, Dinulos JE, Cosar D, Shaker M, Shah SJ, Gainor JF, Temel JS, Lei M, Inker LA, Fintelmann FJ, Sise ME) J Natl Compr Canc Netw 2025 Jul 30;23(9):393-400 2 Citations |
| 1 | Nephrotoxicity Surveillance for Childhood and Young Adult Survivors of Cancer: Recommendations From the International Late Effects of Childhood Cancer Guideline Harmonization Group. (Kooijmans ECM, Mulder RL, Marks SD, Pavasovic V, Motwani SS, Walwyn T, Larkins NG, Kruseova J, Constine LS, Wallace WH, Green DM, Bökenkamp A, van der Pal HJH, van den Heuvel-Eibrink MM, Hjorth L, Andrés-Jensen L, Bardi E, van Dalen EC, Demoor-Goldschmidt C, Becktell K, Grönroos M, Kieran K, Mironova D, Terenziani M, Veening MA, Zieg J, Onder S, Onder AM, Routh JC, Thompson J, Hudson MM, Kremer LCM, Skinner R, Ehrhardt MJ) J Clin Oncol 2025 Jul 20;43(21):2433-2448 5 Citations |
| 1 | Modulation of blood-tumor barrier transcriptional programs improves intratumoral drug delivery and potentiates chemotherapy in GBM. (Jimenez-Macias JL, Vaughn-Beaucaire P, Bharati A, Xu Z, Forrest M, Hong J, Sun M, Schmidt A, Clark J, Hawkins W, Mercado N, Real J, Huntington K, Zdioruk M, Nowicki MO, Cho CF, Wu B, Li W, Logan T, Manz KE, Pennell KD, Fedeles BI, Bertone P, Punsoni M, Brodsky AS, Lawler SE) Sci Adv 2025 Feb 28;11(9):eadr1481 8 Citations |
| 1 | KRAS mutants confer platinum resistance by regulating ALKBH5 posttranslational modifications in lung cancer. (Yu F, Zheng S, Yu C, Gao S, Shen Z, Nar R, Liu Z, Huang S, Wu L, Gu T, Qian Z) J Clin Invest 2025 Feb 04;135(6) 24 Citations |
| 1 | Factors associated with longitudinal progression of the cumulative burden of morbidity and overall mortality after cisplatin-based chemotherapy for testicular cancer. (Kerns SL, Dinh PC Jr, Monahan PO, Stump T, Fung C, Sesso HD, Feldman DR, Hamilton RJ, Vaughn DJ, Huddart R, Kollmannsberger C, Martin NE, Nevel K, Kincaid J, Einhorn LH, Travis LB) J Natl Cancer Inst 2025 Sep 01;117(9):1797-1808 3 Citations |
| 1 | Lack of Cannabinoid Type 2 Promoter Activity in Normal or Injured Kidneys Using a Cnr2-GFP Reporter Mouse. (Boals AG, Collier DM, Romero JR, Hillard CJ, Park F) Cannabis Cannabinoid Res 2025 Jun;10(3):400-408 3 Citations |
| 1 | Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer. (Powles T, Catto JWF, Galsky MD, Al-Ahmadie H, Meeks JJ, Nishiyama H, Vu TQ, Antonuzzo L, Wiechno P, Atduev V, Kann AG, Kim TH, Suárez C, Chang CH, Roghmann F, Özgüroğlu M, Eigl BJ, Oliveira N, Buchler T, Gadot M, Zakharia Y, Armstrong J, Gupta A, Hois S, van der Heijden MS, NIAGARA Investigators) N Engl J Med 2024 Nov 14;391(19):1773-1786 268 Citations |
| 1 | Patient-reported outcomes (PROs) in NRG Oncology RTOG 0436: a phase III trial evaluating the addition of cetuximab to paclitaxel, cisplatin, and radiation for esophageal cancer treated without surgery. (Kachnic LA, Winter K, Suntharalingam M, Ilson D, Konski A, Lloyd S, McAvoy SA, Lad T, Olowokure OG, Samson P, Gore EM, Meyer JE, Videtic GMM, Clump DA, Raben A, Kayaleh O, Barker J Jr, Haddock MG, Hopkins JO, Bruner DW) Qual Life Res 2024 Oct;33(10):2833-2844 2 Citations |
| 1 | Concurrent durvalumab and radiation therapy (DUART) followed by adjuvant durvalumab in patients with localized urothelial cancer of bladder: results from phase II study, BTCRC-GU15-023. (Joshi M, Tuanquin L, Zhu J, Walter V, Schell T, Kaag M, Kilari D, Liao J, Holder SL, Emamekhoo H, Sankin A, Merrill S, Zheng H, Warrick J, Hauke R, Gartrel B, Stein M, Drabick J, Degraff DJ, Zakharia Y) J Immunother Cancer 2023 Feb;11(2) 25 Citations |
| 1 | Avasopasem manganese (GC4419) protects against cisplatin-induced chronic kidney disease: An exploratory analysis of renal metrics from a randomized phase 2b clinical trial in head and neck cancer patients. (Mapuskar KA, Vasquez Martinez G, Pulliam CF, Petronek MS, Steinbach EJ, Monga V, Furqan M, Jetton JG, Saunders DP, Pearce A, Davidson S, Pitre L, Dunlap NE, Fairbanks R, Lee CM, Mott SL, Bodeker KL, Cl H, Buatti JM, Anderson CM, Beardsley RA, Holmlund JT, Zepeda-Orozco D, Spitz DR, Allen BG) Redox Biol 2023 Apr;60:102599 16 Citations |
| 1 | DNA damage is overcome by TRIP13 overexpression during cisplatin nephrotoxicity. (Hama T, Nagesh PK, Chowdhury P, Moore BM 2nd, Yallapu MM, Regner KR, Park F) JCI Insight 2021 Nov 22;6(22) 10 Citations |
| 1 | Risk groups of laryngeal cancer treated with chemoradiation according to nomogram scores - A pooled analysis of RTOG 0129 and 0522. (Awan MJ, Gittleman H, Barnholtz-Sloan J, Machtay M, Nguyen-Tan PF, Rosenthal DI, Schultz C, Huth BJ, Thorstad WL, Frank SJ, Kim H, Foote RL, Lango MN, Shenouda G, Suntharalingam M, Harris J, Zhang Q, Le QT, Yao M, NRG Oncology Group) Oral Oncol 2021 May;116:105241 5 Citations |
| 1 | Subsequent malignant neoplasms among children with Hodgkin lymphoma: a report from the Children's Oncology Group. (Giulino-Roth L, Pei Q, Buxton A, Bush R, Wu Y, Wolden SL, Constine LS, Kelly KM, Schwartz CL, Friedman DL) Blood 2021 Mar 18;137(11):1449-1456 24 Citations |
| 1 | miRNAs Modulate the Dichotomy of Cisplatin Resistance or Sensitivity in Breast Cancer: An Update of Therapeutic Implications. (Safi A, Bastami M, Delghir S, Ilkhani K, Seif F, Alivand MR) Anticancer Agents Med Chem 2021;21(9):1069-1081 9 Citations |
| 1 | Correlation of CT texture changes with treatment response during radiation therapy for esophageal cancer: An exploratory study. (Yan Z, Zhang J, Long H, Sun X, Li D, Tang T, Li XA, Hui W) PLoS One 2019;14(9):e0223140 8 Citations |
| 1 | GnRH-R-Targeted Lytic Peptide Sensitizes BRCA Wild-type Ovarian Cancer to PARP Inhibition. (Ma S, Pradeep S, Villar-Prados A, Wen Y, Bayraktar E, Mangala LS, Kim MS, Wu SY, Hu W, Rodriguez-Aguayo C, Leuschner C, Liang X, Ram PT, Schlacher K, Coleman RL, Sood AK) Mol Cancer Ther 2019 May;18(5):969-979 18 Citations |
| 1 | Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort. (Smeland S, Bielack SS, Whelan J, Bernstein M, Hogendoorn P, Krailo MD, Gorlick R, Janeway KA, Ingleby FC, Anninga J, Antal I, Arndt C, Brown KLB, Butterfass-Bahloul T, Calaminus G, Capra M, Dhooge C, Eriksson M, Flanagan AM, Friedel G, Gebhardt MC, Gelderblom H, Goldsby R, Grier HE, Grimer R, Hawkins DS, Hecker-Nolting S, Sundby Hall K, Isakoff MS, Jovic G, Kühne T, Kager L, von Kalle T, Kabickova E, Lang S, Lau CC, Leavey PJ, Lessnick SL, Mascarenhas L, Mayer-Steinacker R, Meyers PA, Nagarajan R, Randall RL, Reichardt P, Renard M, Rechnitzer C, Schwartz CL, Strauss S, Teot L, Timmermann B, Sydes MR, Marina N) Eur J Cancer 2019 Mar;109:36-50 583 Citations |
| 1 | Adjuvant carboplatin and paclitaxel after concurrent cisplatin and radiotherapy in patients with locally advanced cervical cancer. (Yavas G, Yavas C, Sen E, Oner I, Celik C, Ata O) Int J Gynecol Cancer 2019 Jan;29(1):42-47 31 Citations |
| 1 | Pericardial effusion in Hodgkin lymphoma: a report from the Children's Oncology Group AHOD0031 protocol. (Marks LJ, McCarten KM, Pei Q, Friedman DL, Schwartz CL, Kelly KM) Blood 2018 Sep 13;132(11):1208-1211 14 Citations |
| 1 | Patterns of Involved-Field Radiation Therapy Protocol Deviations in Pediatric Versus Adolescent and Young Adults With Hodgkin Lymphoma: A Report From the Children's Oncology Group AHOD0031. (Parzuchowski A, Bush R, Pei Q, Friedman DL, FitzGerald TJ, Wolden SL, Dharmarajan KV, Constine LS, Laurie F, Kessel SK, Appel B, Fernandez K, Punnett A, Schwartz CL, Cox J, Terezakis SA) Int J Radiat Oncol Biol Phys 2018 Apr 01;100(5):1119-1125 6 Citations |
| 1 | Cumulative Burden of Morbidity Among Testicular Cancer Survivors After Standard Cisplatin-Based Chemotherapy: A Multi-Institutional Study. (Kerns SL, Fung C, Monahan PO, Ardeshir-Rouhani-Fard S, Abu Zaid MI, Williams AM, Stump TE, Sesso HD, Feldman DR, Hamilton RJ, Vaughn DJ, Beard C, Huddart RA, Kim J, Kollmannsberger C, Sahasrabudhe DM, Cook R, Fossa SD, Einhorn LH, Travis LB, Platinum Study Group) J Clin Oncol 2018 May 20;36(15):1505-1512 110 Citations |
| 2 | Final results of a multi-institutional phase II trial of reirradiation with concurrent weekly cisplatin and cetuximab for recurrent or second primary squamous cell carcinoma of the head and neck. (Awan MJ, Nedzi L, Wang D, Tumati V, Sumer B, Xie XJ, Smith I, Truelson J, Hughes R, Myers LL, Lavertu P, Wong S, Yao M) Ann Oncol 2018 Apr 01;29(4):998-1003 23 Citations |
| 1 | Multi-Institutional Assessment of Adverse Health Outcomes Among North American Testicular Cancer Survivors After Modern Cisplatin-Based Chemotherapy. (Fung C, Sesso HD, Williams AM, Kerns SL, Monahan P, Abu Zaid M, Feldman DR, Hamilton RJ, Vaughn DJ, Beard CJ, Kollmannsberger CK, Cook R, Althouse S, Ardeshir-Rouhani-Fard S, Lipshultz SE, Einhorn LH, Fossa SD, Travis LB, Platinum Study Group) J Clin Oncol 2017 Apr 10;35(11):1211-1222 92 Citations |
| 1 | Wwox-Brca1 interaction: role in DNA repair pathway choice. (Schrock MS, Batar B, Lee J, Druck T, Ferguson B, Cho JH, Akakpo K, Hagrass H, Heerema NA, Xia F, Parvin JD, Aldaz CM, Huebner K) Oncogene 2017 Apr 20;36(16):2215-2227 46 Citations |
| 1 | Quality of Life and Performance Status From a Substudy Conducted Within a Prospective Phase 3 Randomized Trial of Concurrent Standard Radiation Versus Accelerated Radiation Plus Cisplatin for Locally Advanced Head and Neck Carcinoma: NRG Oncology RTOG 0129. (Xiao C, Zhang Q, Nguyen-Tân PF, List M, Weber RS, Ang KK, Rosenthal D, Filion EJ, Kim H, Silverman C, Raben A, Galloway T, Fortin A, Gore E, Winquist E, Jones CU, Robinson W, Raben D, Le QT, Bruner D) Int J Radiat Oncol Biol Phys 2017 Mar 15;97(4):667-677 35 Citations |
| 1 | Comprehensive Audiometric Analysis of Hearing Impairment and Tinnitus After Cisplatin-Based Chemotherapy in Survivors of Adult-Onset Cancer. (Frisina RD, Wheeler HE, Fossa SD, Kerns SL, Fung C, Sesso HD, Monahan PO, Feldman DR, Hamilton R, Vaughn DJ, Beard CJ, Budnick A, Johnson EM, Ardeshir-Rouhani-Fard S, Einhorn LH, Lipshultz SE, Dolan ME, Travis LB) J Clin Oncol 2016 Aug 10;34(23):2712-20 245 Citations |
| 2 | The lncRNA PVT1 Contributes to the Cervical Cancer Phenotype and Associates with Poor Patient Prognosis. (Iden M, Fye S, Li K, Chowdhury T, Ramchandran R, Rader JS) PLoS One 2016;11(5):e0156274 146 Citations |
| 1 | Platinum Concentration and Pathologic Response to Cisplatin-Based Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer. (Guancial EA, Kilari D, Xiao GQ, Abu-Farsakh SH, Baran A, Messing EM, Kim ES) PLoS One 2016;11(5):e0155503 7 Citations |
| 1 | Clinical Evaluation of Cisplatin Sensitivity of Germline Polymorphisms in Neoadjuvant Chemotherapy for Urothelial Cancer. (O'Donnell PH, Alanee S, Stratton KL, Garcia-Grossman IR, Cao H, Ostrovnaya I, Plimack ER, Manschreck C, Ganshert C, Smith ND, Steinberg GD, Vijai J, Offit K, Stadler WM, Bajorin DF) Clin Genitourin Cancer 2016 Dec;14(6):511-517 5 Citations |
| 1 | Intensified Chemotherapy With Dexrazoxane Cardioprotection in Newly Diagnosed Nonmetastatic Osteosarcoma: A Report From the Children's Oncology Group. (Schwartz CL, Wexler LH, Krailo MD, Teot LA, Devidas M, Steinherz LJ, Goorin AM, Gebhardt MC, Healey JH, Sato JK, Meyers PA, Grier HE, Bernstein ML, Lipshultz SE) Pediatr Blood Cancer 2016 Jan;63(1):54-61 85 Citations |
| 1 | Prognostic factors modifying the treatment-free interval in recurrent ovarian cancer. (Eng KH, Hanlon BM, Bradley WH, Szender JB) Gynecol Oncol 2015 Nov;139(2):228-35 30 Citations |
| 1 | Valproic acid suppresses the self-renewal and proliferation of head and neck cancer stem cells. (Lee SH, Nam HJ, Kang HJ, Samuels TL, Johnston N, Lim YC) Oncol Rep 2015 Oct;34(4):2065-71 21 Citations |
| 1 | Targeting c-MYC in Platinum-Resistant Ovarian Cancer. (Reyes-González JM, Armaiz-Peña GN, Mangala LS, Valiyeva F, Ivan C, Pradeep S, Echevarría-Vargas IM, Rivera-Reyes A, Sood AK, Vivas-Mejía PE) Mol Cancer Ther 2015 Oct;14(10):2260-9 116 Citations |
| 1 | A nomogram predicting the cancer-specific mortality in patients eligible for radical cystectomy evaluating clinical data and neoadjuvant cisplatinum-based chemotherapy. (Di Trapani E, Sanchez-Salas R, Gandaglia G, Rocchini L, Moschini M, Lizee D, Carneiro A, Sivaraman A, Barret E, Rozet F, Galiano M, Bennamoun M, Colombo R, Suardi N, Briganti A, Montorsi F, Cathelineau X) World J Urol 2016 Feb;34(2):207-13 17 Citations |
| 1 | NRG Oncology/RTOG 0921: A phase 2 study of postoperative intensity-modulated radiotherapy with concurrent cisplatin and bevacizumab followed by carboplatin and paclitaxel for patients with endometrial cancer. (Viswanathan AN, Moughan J, Miller BE, Xiao Y, Jhingran A, Portelance L, Bosch WR, Matulonis UA, Horowitz NS, Mannel RS, Souhami L, Erickson BA, Winter KA, Small W Jr, Gaffney DK) Cancer 2015 Jul 01;121(13):2156-63 51 Citations |
| 1 | Characterization of Anthropometric Changes that Occur During Neoadjuvant Therapy for Potentially Resectable Pancreatic Cancer. (Cooper AB, Slack R, Fogelman D, Holmes HM, Petzel M, Parker N, Balachandran A, Garg N, Ngo-Huang A, Varadhachary G, Evans DB, Lee JE, Aloia T, Conrad C, Vauthey JN, Fleming JB, Katz MH) Ann Surg Oncol 2015 Jul;22(7):2416-23 139 Citations |
| 2 | Copy number gain of hsa-miR-569 at 3q26.2 leads to loss of TP53INP1 and aggressiveness of epithelial cancers. (Chaluvally-Raghavan P, Zhang F, Pradeep S, Hamilton MP, Zhao X, Rupaimoole R, Moss T, Lu Y, Yu S, Pecot CV, Aure MR, Peuget S, Rodriguez-Aguayo C, Han HD, Zhang D, Venkatanarayan A, Krohn M, Kristensen VN, Gagea M, Ram P, Liu W, Lopez-Berestein G, Lorenzi PL, Børresen-Dale AL, Chin K, Gray J, Dusetti NJ, McGuire SE, Flores ER, Sood AK, Mills GB) Cancer Cell 2014 Dec 08;26(6):863-879 50 Citations |
| 4 | Cisplatin and etoposide versus carboplatin and paclitaxel with concurrent radiotherapy for stage III non-small-cell lung cancer: an analysis of Veterans Health Administration data. (Santana-Davila R, Devisetty K, Szabo A, Sparapani R, Arce-Lara C, Gore EM, Moran A, Williams CD, Kelley MJ, Whittle J) J Clin Oncol 2015 Feb 20;33(6):567-74 121 Citations |
| 1 | Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the Radiation Therapy Oncology Group 0129 trial: long-term report of efficacy and toxicity. (Nguyen-Tan PF, Zhang Q, Ang KK, Weber RS, Rosenthal DI, Soulieres D, Kim H, Silverman C, Raben A, Galloway TJ, Fortin A, Gore E, Westra WH, Chung CH, Jordan RC, Gillison ML, List M, Le QT) J Clin Oncol 2014 Dec 01;32(34):3858-66 427 Citations |
| 1 | Dose-intensive response-based chemotherapy and radiation therapy for children and adolescents with newly diagnosed intermediate-risk hodgkin lymphoma: a report from the Children's Oncology Group Study AHOD0031. (Friedman DL, Chen L, Wolden S, Buxton A, McCarten K, FitzGerald TJ, Kessel S, De Alarcon PA, Chen AR, Kobrinsky N, Ehrlich P, Hutchison RE, Constine LS, Schwartz CL) J Clin Oncol 2014 Nov 10;32(32):3651-8 234 Citations |
| 1 | Heat shock protein-mediated protection against Cisplatin-induced hair cell death. (Baker TG, Roy S, Brandon CS, Kramarenko IK, Francis SP, Taleb M, Marshall KM, Schwendener R, Lee FS, Cunningham LL) J Assoc Res Otolaryngol 2015 Feb;16(1):67-80 37 Citations |
| 2 | Molecular profiling in gastric cancer: examining potential targets for chemotherapy. (Miura JT, Johnston FM, Thomas J, George B, Eastwood D, Tsai S, Christians KK, Turaga KK, Gamblin TC) J Surg Oncol 2014 Sep;110(3):302-6 9 Citations |
| 1 | Copper transporter CTR1 expression and tissue platinum concentration in non-small cell lung cancer. (Kim ES, Tang X, Peterson DR, Kilari D, Chow CW, Fujimoto J, Kalhor N, Swisher SG, Stewart DJ, Wistuba II, Siddik ZH) Lung Cancer 2014 Jul;85(1):88-93 84 Citations |
| 2 | Cisplatin versus carboplatin-based regimens for the treatment of patients with metastatic lung cancer. An analysis of Veterans Health Administration data. (Santana-Davila R, Szabo A, Arce-Lara C, Williams CD, Kelley MJ, Whittle J) J Thorac Oncol 2014 May;9(5):702-9 51 Citations |
| 1 | HE4 (WFDC2) gene overexpression promotes ovarian tumor growth. (Moore RG, Hill EK, Horan T, Yano N, Kim K, MacLaughlan S, Lambert-Messerlian G, Tseng YD, Padbury JF, Miller MC, Lange TS, Singh RK) Sci Rep 2014 Jan 06;4:3574 88 Citations |
| 1 | Optimization of carboxylate-terminated poly(amidoamine) dendrimer-mediated cisplatin formulation. (Kulhari H, Pooja D, Singh MK, Chauhan AS) Drug Dev Ind Pharm 2015 Feb;41(2):232-8 55 Citations |
| 1 | Treatment sequencing for resectable pancreatic cancer: influence of early metastases and surgical complications on multimodality therapy completion and survival. (Tzeng CW, Tran Cao HS, Lee JE, Pisters PW, Varadhachary GR, Wolff RA, Abbruzzese JL, Crane CH, Evans DB, Wang H, Abbott DE, Vauthey JN, Aloia TA, Fleming JB, Katz MH) J Gastrointest Surg 2014 Jan;18(1):16-24; discussion 24-5 186 Citations |
| 1 | α5-GABAA receptors negatively regulate MYC-amplified medulloblastoma growth. (Sengupta S, Weeraratne SD, Sun H, Phallen J, Rallapalli SK, Teider N, Kosaras B, Amani V, Pierre-Francois J, Tang Y, Nguyen B, Yu F, Schubert S, Balansay B, Mathios D, Lechpammer M, Archer TC, Tran P, Reimer RJ, Cook JM, Lim M, Jensen FE, Pomeroy SL, Cho YJ) Acta Neuropathol 2014 Apr;127(4):593-603 53 Citations |
| 1 | Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer. (Zighelboim I, Wright JD, Gao F, Case AS, Massad LS, Mutch DG, Powell MA, Thaker PH, Eisenhauer EL, Cohn DE, Valea FA, Alvarez Secord A, Lippmann LT, Dehdashti F, Rader JS) Gynecol Oncol 2013 Jul;130(1):64-8 79 Citations |
| 1 | Statistical model for prediction of hearing loss in patients receiving cisplatin chemotherapy. (Johnson A, Tarima S, Wong S, Friedland DR, Runge CL) JAMA Otolaryngol Head Neck Surg 2013 Mar;139(3):256-64 15 Citations |
| 1 | Mechanistic basis for overcoming platinum resistance using copper chelating agents. (Liang ZD, Long Y, Tsai WB, Fu S, Kurzrock R, Gagea-Iurascu M, Zhang F, Chen HH, Hennessy BT, Mills GB, Savaraj N, Kuo MT) Mol Cancer Ther 2012 Nov;11(11):2483-94 73 Citations |
| 1 | Genome-wide association study of prognosis in advanced non-small cell lung cancer patients receiving platinum-based chemotherapy. (Hu L, Wu C, Zhao X, Heist R, Su L, Zhao Y, Han B, Cao S, Chu M, Dai J, Dong J, Shu Y, Xu L, Chen Y, Wang Y, Lu F, Jiang Y, Yu D, Chen H, Tan W, Ma H, Chen J, Jin G, Wu T, Lu D, Christiani DC, Lin D, Hu Z, Shen H) Clin Cancer Res 2012 Oct 01;18(19):5507-14 55 Citations |
| 1 | Long-term follow-up of the RTOG 9501/intergroup phase III trial: postoperative concurrent radiation therapy and chemotherapy in high-risk squamous cell carcinoma of the head and neck. (Cooper JS, Zhang Q, Pajak TF, Forastiere AA, Jacobs J, Saxman SB, Kish JA, Kim HE, Cmelak AJ, Rotman M, Lustig R, Ensley JF, Thorstad W, Schultz CJ, Yom SS, Ang KK) Int J Radiat Oncol Biol Phys 2012 Dec 01;84(5):1198-205 499 Citations |
| 1 | Cisplatin nephrotoxicity involves mitochondrial injury with impaired tubular mitochondrial enzyme activity. (Zsengellér ZK, Ellezian L, Brown D, Horváth B, Mukhopadhyay P, Kalyanaraman B, Parikh SM, Karumanchi SA, Stillman IE, Pacher P) J Histochem Cytochem 2012 Jul;60(7):521-9 109 Citations |
| 1 | Risk factors for cisplatin-associated ototoxicity in pediatric oncology patients. (Yancey A, Harris MS, Egbelakin A, Gilbert J, Pisoni DB, Renbarger J) Pediatr Blood Cancer 2012 Jul 15;59(1):144-8 136 Citations |
| 2 | Mitochondrial-targeted antioxidants represent a promising approach for prevention of cisplatin-induced nephropathy. (Mukhopadhyay P, Horváth B, Zsengellér Z, Zielonka J, Tanchian G, Holovac E, Kechrid M, Patel V, Stillman IE, Parikh SM, Joseph J, Kalyanaraman B, Pacher P) Free Radic Biol Med 2012 Jan 15;52(2):497-506 192 Citations |
| 1 | Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. (Curran WJ Jr, Paulus R, Langer CJ, Komaki R, Lee JS, Hauser S, Movsas B, Wasserman T, Rosenthal SA, Gore E, Machtay M, Sause W, Cox JD) J Natl Cancer Inst 2011 Oct 05;103(19):1452-60 1171 Citations |
| 1 | Extended-field irradiation and intracavitary brachytherapy combined with cisplatin and amifostine for cervical cancer with positive para-aortic or high common iliac lymph nodes: results of arm II of Radiation Therapy Oncology Group (RTOG) 0116. (Small W Jr, Winter K, Levenback C, Iyer R, Hymes SR, Jhingran A, Gaffney D, Erickson B, Greven K) Int J Gynecol Cancer 2011 Oct;21(7):1266-75 40 Citations |
| 1 | Cisplatin ototoxicity affecting cochlear implant benefit. (Harris MS, Gilbert JL, Lormore KA, Musunuru SA, Fritsch MH) Otol Neurotol 2011 Aug;32(6):969-72 12 Citations |
| 1 | Survival and quality of life of patients with resected pancreatic adenocarcinoma treated with adjuvant interferon-based chemoradiation: a phase II trial. (Katz MH, Wolff R, Crane CH, Varadhachary G, Javle M, Lin E, Evans DB, Lee JE, Fleming JB, Pisters PW) Ann Surg Oncol 2011 Dec;18(13):3615-22 18 Citations |
| 1 | Regulation of glycosyltransferase genes in apoptotic breast cancer cells induced by L: -PPMP and cisplatin. (Ma R, Hopp EA, Decker NM, Loucks A, Johnson JR, Moskal J, Basu M, Banerjee S, Basu S) Adv Exp Med Biol 2011;705:621-42 4 Citations |
| 1 | How does TPF improve survival over PF? (Devisetty K, Wong SJ, Mell LK) Lancet Oncol 2011 May;12(5):419-20; author reply 421-2 3 Citations |
| 2 | Chemoembolization of intrahepatic cholangiocarcinoma with cisplatinum, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol: a 2-center study. (Kiefer MV, Albert M, McNally M, Robertson M, Sun W, Fraker D, Olthoff K, Christians K, Pappas S, Rilling W, Soulen MC) Cancer 2011 Apr 01;117(7):1498-505 152 Citations |
| 1 | Higher biologically effective dose of radiotherapy is associated with improved outcomes for locally advanced non-small cell lung carcinoma treated with chemoradiation: an analysis of the Radiation Therapy Oncology Group. (Machtay M, Bae K, Movsas B, Paulus R, Gore EM, Komaki R, Albain K, Sause WT, Curran WJ) Int J Radiat Oncol Biol Phys 2012 Jan 01;82(1):425-34 269 Citations |
| 1 | Preclinical and pilot clinical studies of docetaxel chemoradiation for Stage III non-small-cell lung cancer. (Chen Y, Pandya KJ, Hyrien O, Keng PC, Smudzin T, Anderson J, Qazi R, Smith B, Watson TJ, Feins RH, Johnstone DW) Int J Radiat Oncol Biol Phys 2011 Aug 01;80(5):1358-64 7 Citations |
| 1 | Phase I clinical trial of hepatic arterial infusion of cisplatin in combination with intravenous liposomal doxorubicin in patients with advanced cancer and dominant liver involvement. (Tsimberidou AM, Moulder S, Fu S, Wen S, Naing A, Bedikian AY, Daring S, Uehara C, Ng C, Wallace M, Camacho L, Kurzrock R) Cancer Chemother Pharmacol 2010 Nov;66(6):1087-93 17 Citations |
| 2 | Management of borderline resectable pancreatic cancer. (Lal A, Christians K, Evans DB) Surg Oncol Clin N Am 2010 Apr;19(2):359-70 9 Citations |
| 2 | Induction of apoptosis with cisplatin enhances calcium oxalate crystal adherence to inner medullary collecting duct cells. (Kleinman JG, Sorokina EA, Wesson JA) Urol Res 2010 Apr;38(2):97-104 11 Citations |
| 1 | Early postoperative paclitaxel followed by concurrent paclitaxel and cisplatin with radiation therapy for patients with resected high-risk head and neck squamous cell carcinoma: report of the phase II trial RTOG 0024. (Rosenthal DI, Harris J, Forastiere AA, Weber RS, Ridge JA, Myers JN, Garden AS, Kuettel MR, Sidhu K, Schultz CJ, Trotti A, Ang KK) J Clin Oncol 2009 Oct 01;27(28):4727-32 35 Citations |
| 1 | Sequential chemotherapy and irradiation in advanced stage endometrial cancer: A Gynecologic Oncology Group phase I trial of doxorubicin-cisplatin followed by whole abdomen irradiation. (Fowler JM, Brady WE, Grigsby PW, Cohn DE, Mannel RS, Rader JS) Gynecol Oncol 2009 Mar;112(3):553-7 16 Citations |
| 1 | Polymorphisms of p16, p27, p73, and MDM2 modulate response and survival of pancreatic cancer patients treated with preoperative chemoradiation. (Chen J, Li D, Killary AM, Sen S, Amos CI, Evans DB, Abbruzzese JL, Frazier ML) Ann Surg Oncol 2009 Feb;16(2):431-9 47 Citations |
| 1 | Relative contributions of radiation and cisplatin-based chemotherapy to sensorineural hearing loss in head-and-neck cancer patients. (Hitchcock YJ, Tward JD, Szabo A, Bentz BG, Shrieve DC) Int J Radiat Oncol Biol Phys 2009 Mar 01;73(3):779-88 107 Citations |
| 1 | Survival and outcome of blastoid variant myeloma following treatment with the novel thalidomide containing regime DT-PACE. (Srikanth M, Davies FE, Wu P, Jenner MW, Ethell ME, Potter MN, Shaw BE, Saso RM, Dines S, Morgan GJ) Eur J Haematol 2008 Dec;81(6):432-6 21 Citations |
| 1 | Cisplatin, fluorouracil, interferon-alpha, and radiation as adjuvant therapy for resected pancreatic cancer: is there a future for this regimen and/or should we change our approach to research and treatment of patients with pancreatic cancer? (Pisters PW, Evans DB) Ann Surg 2008 Aug;248(2):152-3 4 Citations |
| 1 | Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. (Varadhachary GR, Wolff RA, Crane CH, Sun CC, Lee JE, Pisters PW, Vauthey JN, Abdalla E, Wang H, Staerkel GA, Lee JH, Ross WA, Tamm EP, Bhosale PR, Krishnan S, Das P, Ho L, Xiong H, Abbruzzese JL, Evans DB) J Clin Oncol 2008 Jul 20;26(21):3487-95 438 Citations |
| 1 | Systemic chemotherapy for adrenocortical carcinoma: comparative responses to conventional first-line therapies. (Fareau GG, Lopez A, Stava C, Vassilopoulou-Sellin R) Anticancer Drugs 2008 Jul;19(6):637-44 13 Citations |
| 1 | Single-nucleotide polymorphisms of DNA damage response genes are associated with overall survival in patients with pancreatic cancer. (Okazaki T, Jiao L, Chang P, Evans DB, Abbruzzese JL, Li D) Clin Cancer Res 2008 Apr 01;14(7):2042-8 49 Citations |
| 1 | Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group. (Meyers PA, Schwartz CL, Krailo MD, Healey JH, Bernstein ML, Betcher D, Ferguson WS, Gebhardt MC, Goorin AM, Harris M, Kleinerman E, Link MP, Nadel H, Nieder M, Siegal GP, Weiner MA, Wells RJ, Womer RB, Grier HE, Children's Oncology Group) J Clin Oncol 2008 Feb 01;26(4):633-8 692 Citations |
| 2 | Utility of single versus tandem autotransplants for advanced testes/germ cell cancer: a center for international blood and marrow transplant research (CIBMTR) analysis. (Lazarus HM, Stiff PJ, Carreras J, Logan BR, Akard L, Bolwell BJ, Childs RW, Gale RP, Klein JP, Lill MC, Pérez WS, Stadtmauer EA, Rizzo JD) Biol Blood Marrow Transplant 2007 Jul;13(7):778-89 10 Citations |
| 1 | Extended-field irradiation and intracavitary brachytherapy combined with cisplatin chemotherapy for cervical cancer with positive para-aortic or high common iliac lymph nodes: results of ARM 1 of RTOG 0116. (Small W Jr, Winter K, Levenback C, Iyer R, Gaffney D, Asbell S, Erickson B, Jhingran A, Greven K) Int J Radiat Oncol Biol Phys 2007 Jul 15;68(4):1081-7 129 Citations |
| 1 | Extended safety and efficacy data on S-1 plus cisplatin in patients with untreated, advanced gastric carcinoma in a multicenter phase II study. (Lenz HJ, Lee FC, Haller DG, Singh D, Benson AB 3rd, Strumberg D, Yanagihara R, Yao JC, Phan AT, Ajani JA) Cancer 2007 Jan 01;109(1):33-40 55 Citations |
| 1 | Locally recurrent, previously irradiated head and neck cancer: concurrent re-irradiation and chemotherapy, or chemotherapy alone? (Wong SJ, Machtay M, Li Y) J Clin Oncol 2006 Jun 10;24(17):2653-8 121 Citations |
| 1 | Re: Modified intrapleural cisplatin treatment for lung cancer with positive pleural lavage cytology or malignant effusion, by Muraoka M, Oka T, Akamine S, et al. (Johnstone DW) J Surg Oncol 2006 Mar 15;93(4):255-6 |
| 1 | Multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma. (Ajani JA, Lee FC, Singh DA, Haller DG, Lenz HJ, Benson AB 3rd, Yanagihara R, Phan AT, Yao JC, Strumberg D) J Clin Oncol 2006 Feb 01;24(4):663-7 93 Citations |
| 1 | APE chemotherapy for children with relapsed Hodgkin disease: a Pediatric Oncology Group trial. (Wimmer RS, Chauvenet AR, London WB, Villaluna D, de Alarcon PA, Schwartz CL) Pediatr Blood Cancer 2006 Mar;46(3):320-4 8 Citations |
| 1 | Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. (Meyers PA, Schwartz CL, Krailo M, Kleinerman ES, Betcher D, Bernstein ML, Conrad E, Ferguson W, Gebhardt M, Goorin AM, Harris MB, Healey J, Huvos A, Link M, Montebello J, Nadel H, Nieder M, Sato J, Siegal G, Weiner M, Wells R, Wold L, Womer R, Grier H) J Clin Oncol 2005 Mar 20;23(9):2004-11 673 Citations |
| 1 | Lack of benefit of concurrent chemotherapy in patients with cervical cancer and negative lymph nodes by FDG-PET. (Grigsby PW, Mutch DG, Rader J, Herzog TJ, Zoberi I, Siegel BA, Dehdashti F) Int J Radiat Oncol Biol Phys 2005 Feb 01;61(2):444-9 31 Citations |
| 1 | Patterns of radiotherapy practice for patients with carcinoma of the uterine cervix: a patterns of care study. (Eifel PJ, Moughan J, Erickson B, Iarocci T, Grant D, Owen J) Int J Radiat Oncol Biol Phys 2004 Nov 15;60(4):1144-53 122 Citations |
| 1 | Preliminary results of Radiation Therapy Oncology Group 97-03: a randomized phase ii trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck. (Garden AS, Harris J, Vokes EE, Forastiere AA, Ridge JA, Jones C, Horwitz EM, Glisson BS, Nabell L, Cooper JS, Demas W, Gore E) J Clin Oncol 2004 Jul 15;22(14):2856-64 172 Citations |
| 2 | Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. (Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxman SB, Kish JA, Kim HE, Cmelak AJ, Rotman M, Machtay M, Ensley JF, Chao KS, Schultz CJ, Lee N, Fu KK, Radiation Therapy Oncology Group 9501/Intergroup) N Engl J Med 2004 May 06;350(19):1937-44 2949 Citations |
| 1 | Mantle cell lymphoma in lymph nodes with metastatic small cell carcinoma of lung: a diagnostic and treatment dilemma. (Kampalath B, Abed N, Chitambar CR, Vantuinen P, Chakrabarty G, Hanson G, Rao RN, Shidham VB, Chang CC) Leuk Lymphoma 2004 Feb;45(2):409-14 13 Citations |
| 1 | Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium. (Dreicer R, Manola J, Roth BJ, See WA, Kuross S, Edelman MJ, Hudes GR, Wilding G) Cancer 2004 Apr 15;100(8):1639-45 176 Citations |
| 1 | A phase II study of concomitant hyperfractionated radiation therapy and double dose intra-arterial cisplatin for squamous cell carcinoma of the head and neck. (Regine WF, Valentino J, Arnold SM, Sloan D, Kenady D, Strottmann J, Mohiuddin M) Technol Cancer Res Treat 2002 Apr;1(2):133-40 2 Citations |
| 1 | Phase III study comparing chemotherapy and radiotherapy with preoperative chemotherapy and surgical resection in patients with non-small-cell lung cancer with spread to mediastinal lymph nodes (N2); final report of RTOG 89-01. Radiation Therapy Oncology Group. (Johnstone DW, Byhardt RW, Ettinger D, Scott CB) Int J Radiat Oncol Biol Phys 2002 Oct 01;54(2):365-9 133 Citations |
| 1 | Randomized trial of cisplatin and ifosfamide with or without bleomycin in squamous carcinoma of the cervix: a gynecologic oncology group study. (Bloss JD, Blessing JA, Behrens BC, Mannel RS, Rader JS, Sood AK, Markman M, Benda J) J Clin Oncol 2002 Apr 01;20(7):1832-7 124 Citations |
| 1 | DNA damage invokes mismatch repair-dependent cyclin D1 attenuation and retinoblastoma signaling pathways to inhibit CDK2. (Lan Z, Sever-Chroneos Z, Strobeck MW, Park CH, Baskaran R, Edelmann W, Leone G, Knudsen ES) J Biol Chem 2002 Mar 08;277(10):8372-81 56 Citations |
| 1 | High-dose intra-arterial cisplatin boost with hyperfractionated radiation therapy for advanced squamous cell carcinoma of the head and neck. (Regine WF, Valentino J, Arnold SM, Haydon RC, Sloan D, Kenady D, Strottmann J, Pulmano C, Mohiuddin M) J Clin Oncol 2001 Jul 15;19(14):3333-9 31 Citations |
| 1 | Synergistic action of genistein and cisplatin on growth inhibition and cytotoxicity of human medulloblastoma cells. (Khoshyomn S, Manske GC, Lew SM, Wald SL, Penar PL) Pediatr Neurosurg 2000 Sep;33(3):123-31 38 Citations |
| 1 | The American Brachytherapy Society recommendations for high-dose-rate brachytherapy for carcinoma of the cervix. (Nag S, Erickson B, Thomadsen B, Orton C, Demanes JD, Petereit D) Int J Radiat Oncol Biol Phys 2000 Aug 01;48(1):201-11 445 Citations |
| 1 | Evaluation of gemcitabine in patients with squamous cell carcinoma of the cervix: a Phase II study of the gynecologic oncology group. (Schilder RJ, Blessing JA, Morgan M, Mangan CE, Rader JS) Gynecol Oncol 2000 Feb;76(2):204-7 86 Citations |
| 1 | Enhanced staging and all chemotherapy preoperatively in patients with potentially resectable gastric carcinoma. (Ajani JA, Mansfield PF, Lynch PM, Pisters PW, Feig B, Dumas P, Evans DB, Raijman I, Hargraves K, Curley S, Ota DM) J Clin Oncol 1999 Aug;17(8):2403-11 92 Citations |
| 1 | Inconstant association between 27-kDa heat-shock protein (Hsp27) content and doxorubicin resistance in human colon cancer cells. The doxorubicin-protecting effect of Hsp27. (Garrido C, Mehlen P, Fromentin A, Hammann A, Assem M, Arrigo AP, Chauffert B) Eur J Biochem 1996 May 01;237(3):653-9 81 Citations |
| 1 | Primary squamous cell carcinoma of the breast: sensitivity to cisplatinum-based chemotherapy. (Dejager D, Redlich PN, Dayer AM, Davis HL, Komorowski RA) J Surg Oncol 1995 Jul;59(3):199-203 70 Citations |
| 1 | Circumvention of confluence-dependent resistance in a human multi-drug-resistant colon-cancer cell line. (Garrido C, Chauffert B, Pinard D, Tibaut F, Genne P, Assem M, Dimanche-Boitrel MT) Int J Cancer 1995 Jun 09;61(6):873-9 24 Citations |
| 1 | Serum levels of interleukin-10 in patients with diffuse large cell lymphoma: lack of correlation with prognosis. (Cortes JE, Talpaz M, Cabanillas F, Seymour JF, Kurzrock R) Blood 1995 May 01;85(9):2516-20 56 Citations |
| 1 | Absence of immunohistochemical metallothionein staining in bladder tumor specimens predicts response to neoadjuvant cisplatin, methotrexate and vinblastine chemotherapy. (Bahnson RR, Becich M, Ernstoff MS, Sandlow J, Cohen MB, Williams RD) J Urol 1994 Dec;152(6 Pt 2):2272-5 38 Citations |
| 1 | Deleterious effect of serum proteins on the amphotericin B-induced potentiation of cisplatin in human colon cancer cells. (Assem M, Bonvalot S, Beltramo JL, Garrido C, Dimanche-Boitrel MT, Genne P, Rebibou JM, Caillot D, Chauffert B) Br J Cancer 1994 Oct;70(4):631-5 22 Citations |
| 1 | DNA ploidy and P-glycoprotein expression as predictive factors of response to neoadjuvant chemotherapy for invasive bladder cancer. (Sandlow J, Cohen MB, Robinson RA, Dreicer R, Williams RD) Urology 1994 Jun;43(6):787-91 16 Citations |
| 1 | Acute tumor lysis syndrome and treatment response in patients treated for refractory chronic lymphocytic leukemia with short-course, high-dose cytosine arabinoside, cisplatin, and etoposide. (McCroskey RD, Mosher DF, Spencer CD, Prendergast E, Longo WL) Cancer 1990 Jul 15;66(2):246-50 39 Citations |
| 1 | Cisplatin and myoelectric activity. (Lang IM) Dig Dis Sci 1988 Oct;33(10):1342-3 |
| 1 | Cyst formation in metanephric organ culture induced by cis-dichlorodiammineplatinum (II). (Avner ED, Sweeney WE Jr, Ellis D) Experientia 1983 Jan 15;39(1):74-6 9 Citations |
| 1 | Clinical evaluation of sequentially scheduled cisplatin and VM26 in neuroblastoma: response and toxicity. (Hayes FA, Green AA, Casper J, Cornet J, Evans WE) Cancer 1981 Oct 15;48(8):1715-8 93 Citations |
